首页> 外文学位 >Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer

【24h】

Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？

获取原文

获取原文并翻译 | 示例

页面导航

著录项
相似文献
相关主题

著录项

作者
Gornjec, Andreja.;
展开▼
作者单位

Univerza v Mariboru (Slovenia).;

展开▼
授予单位 Univerza v Mariboru (Slovenia).;
学科
学位 Ph.D.
年度 2020
页码 101 p.
总页数 101
原文格式 PDF
正文语种 eng
中图分类 AAI28175780;
关键词
入库时间 2022-08-17 12:01:12

相似文献

外文文献
中文文献
专利

1. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [J] . van der Biessen Diane A. J., Gietema Jourik A., de Jonge Maja J. A., Investigational new drugs. . 2018,第5期

机译：通过BRCA1 / 2突变和高级浆液卵巢，输卵管或原发性腹膜癌，对PARP抑制剂ABT-767进行PARP抑制剂ABT-767的研究
2. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer [J] . Mittapalli Rajendar K., Nuthalapati Silpa, Shepherd Stacie Peacock, Cancer chemotherapy and pharmacology. . 2017,第3期

机译：BRCA1或BRCA2突变载体中ABT-767的人口药代动力学，具有晚期实体瘤或具有高级浆液卵巢，原发性腹膜或输卵管癌的受试者
3. Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations [J] . ANDREW GARCIA, COREY FRAHM, JOANNE M. JETER, Journal of the advanced practitioner in oncology . 2019,第5期

机译：在卵巢，输卵管管或原发性腹膜癌患者中对卡铂或紫杉醇的过敏反应发生率，或没有BRCA1或BRCA2突变
4. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian fallopian tube or primary peritoneal cancer [O] . Diane A. J. van der Biessen, Jourik A. Gietema, Maja J. A. de Jonge, -1

机译：PARP抑制剂ABT-767在具有BRCA1 / 2突变和高度浆液性卵巢癌输卵管癌或原发性腹膜癌的晚期实体瘤中的1期研究
5. Comparison of Hypersensitivity Reaction Incidence to Carboplatin in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer with or without the BRCA1 or BRCA2 Mutations [O] . Garcia Andrew, Corey Frahm 2017

机译：具有或不具有BRCA1或BRCA2突变的卵巢癌，输卵管癌或原发性腹膜癌患者对卡铂的超敏反应发生率的比较

Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer

著录项

相似文献

相关主题

期刊订阅